HESI AT THIRTY: THE PAST, PRESENT AND FUTURE OF COLLABORATIVE SCIENCE
The Westin - Alexandria, VA
Tuesday 11 June 2019
Welcome & Meeting Goals
Why HESI Matters: A Perspective on 30 Years of Collaborative Science and Its Role Today
Dr. Lois Lehman-McKeeman, Bristol-Myers Squibb, HESI Chair of Board
HESI CITE Lectures – Moderator: Charlene McQueen, University of Arizona, HESI President. The HESI Combining Interdisciplinary and Translational Expertise (CITE) initiative is an ongoing outreach series that promotes discussion and progress on opportunities for, and challenges in, the application of interdisciplinary, multidisciplinary, and translational sciences to improve human and environmental health outcomes.
The Exposome: Measuring Exposures on a Global Scale
Dr. Gary Miller, Vice Dean for Research Strategy and Innovation, Mailman School of Public Health, Columbia University
Acceptable Failure, Innovation & Multidisciplinary Research
Dr. Martin Philbert, Provost, University of Michigan
What will collaborative, multidisciplinary science look like in 2030? How will it adapt and respond to changing scientific, economic, and societal opportunities and pressures?
Moderator: Dr. Martin Philbert; Panelists: Dr. Gary Miller (Columbia University, USA), Dr. Maya Leventer-Roberts (Clalit Research Institute, Israel), Dr. Ned Wakeman (Alderly Park Accelerator, UK), and Dr. Flavio Zambrone (State University of Campinas, Brazil)
HESI Scientific Committee Leadership Working Session
The Future of HESI Science: Where is HESI's programming headed?
Dr. Syril Pettit, HESI Executive Director, and Dr. Michelle Embry, HESI Associate Director
Featured Program Developments at HESI – This session highlights selected HESI scientific programs that have achieved key milestones and/or are actively pursuing new research programs (25 minutes each including questions). Moderator: Dr. Jon Cook, Pfizer, HESI Vice President.
RNAi, Cancer, and Non-Coding RNA: From Discovery into Application for Health
Keynote Speaker – Dr. Gregory Hannon, Cancer Research UK, Cambridge Institute
Introduced by Dr. Tim Gant, Public Health England, Chair of HESI Emerging Issues Committee
30th Anniversary Dinner Reception – Hummingbird Restaurant, Alexandria, Virginia
Wednesday 12 June 2019
Can cancer risk assessment keep pace with evolving science and modalities? This session will explore the evolving landscape of tools, frameworks, and weight of evidence necessary to assess safety for evolving scientific modalities and methodologies from a carcinogenicity perspective. Moderator: Dr. Martin van den Berg, University of Utrecht, HESI Vice-Chair of Board.
HESI’s Foundational Efforts in Cancer Risk Assessment & Transitions to Today
Dr. Samuel Cohen, University of Nebraska Medical Center
Carcinogenomic Approaches to Cancer Risk Assessment: Ready for Prime Time?
Dr. Jan Willem van der Laan, Medicines Evaluation Board
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.